Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Lin

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
JCI Insight|July 24, 2019
Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancerMeifang Yu, Nicholas D Nguyen, Yanqing Huang, et al.
Cancer Research|May 3, 2019
Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic CancerTara N Fujimoto, Lauren E Colbert, Yanqing Huang, et al.
Scientific Reports|February 15, 2019
Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated RadiationJessica M Molkentine, Tara N Fujimoto, Thomas D Horvath, et al.
Advances in Radiation Oncology|December 22, 2021
Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern EraJoseph Abi Jaoude, Connor P Thunshelle, Ramez Kouzy, et al.
Clinical Genitourinary Cancer|January 29, 2023
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder CancerDimitrios Makrakis, Jonathan L Wright, Martine P Roudier, et al.
Cancer Chemotherapy and Pharmacology|August 9, 2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutatedTanner J Freeman, Thomas J George, Samuel A Jacobs, et al.
Nature Communications|July 7, 2022
Mutations in DNA polymerase δ subunit 1 co-segregate with CMD2-type resistance to Cassava Mosaic GeminivirusesYi-Wen Lim, Ben N Mansfeld, Pascal Schläpfer, et al.
Advances in Radiation Oncology|April 29, 2021
Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic CancerShalini Moningi, Joseph Abi Jaoude, Ramez Kouzy, et al.
Gastroenterology|February 26, 2022
Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer MicroenvironmentCarolina J Garcia Garcia, Yanqing Huang, Natividad R Fuentes, et al.
Brachytherapy|December 21, 2023
Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapyGohar S Manzar, Molly B El Alam, Erica J Lynn, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
JCI Insight|July 24, 2019
Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancerMeifang Yu, Nicholas D Nguyen, Yanqing Huang, et al.
Cancer Research|May 3, 2019
Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic CancerTara N Fujimoto, Lauren E Colbert, Yanqing Huang, et al.
Scientific Reports|February 15, 2019
Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated RadiationJessica M Molkentine, Tara N Fujimoto, Thomas D Horvath, et al.
Advances in Radiation Oncology|December 22, 2021
Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern EraJoseph Abi Jaoude, Connor P Thunshelle, Ramez Kouzy, et al.
Clinical Genitourinary Cancer|January 29, 2023
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder CancerDimitrios Makrakis, Jonathan L Wright, Martine P Roudier, et al.
Cancer Chemotherapy and Pharmacology|August 9, 2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutatedTanner J Freeman, Thomas J George, Samuel A Jacobs, et al.
Nature Communications|July 7, 2022
Mutations in DNA polymerase δ subunit 1 co-segregate with CMD2-type resistance to Cassava Mosaic GeminivirusesYi-Wen Lim, Ben N Mansfeld, Pascal Schläpfer, et al.
Advances in Radiation Oncology|April 29, 2021
Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic CancerShalini Moningi, Joseph Abi Jaoude, Ramez Kouzy, et al.
Gastroenterology|February 26, 2022
Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer MicroenvironmentCarolina J Garcia Garcia, Yanqing Huang, Natividad R Fuentes, et al.
Brachytherapy|December 21, 2023
Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapyGohar S Manzar, Molly B El Alam, Erica J Lynn, et al.
Pageof 14